Balixafortide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205864

CAS#: 1051366-32-5

Description: Balixafortide, also known as POL6326, is an orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. CXCR4 inhibitor POL6326 binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types.


Price and Availability

Size
Price

Size
Price

Size
Price

Balixafortide is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 205864
Name: Balixafortide
CAS#: 1051366-32-5
Chemical Formula: C80H112N22O21S2
Exact Mass: 1780.7814
Molecular Weight: 1782.029
Elemental Analysis: C, 53.92; H, 6.34; N, 17.29; O, 18.85; S, 3.60


Synonym: POL6326; POL 6326; POL6326; Balixafortide; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2->9)-disulfide

IUPAC/Chemical Name: Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2->9)-disulfide

InChi Key: UUTLJGUXRVWOSI-YYXAXUJHSA-N

InChi Code: InChI=1S/C80H112N22O21S2/c1-42(82)65(108)98-59-39-124-125-40-60(99-70(113)55(34-45-16-22-49(105)23-17-45)93-66(109)51(10-5-29-87-80(84)85)91-74(117)61-11-6-30-100(61)76(119)43(2)89-71(114)58(38-103)97-73(59)116)72(115)94-54(33-44-14-20-48(104)21-15-44)68(111)90-52(26-27-64(83)107)67(110)92-53(9-3-4-28-81)77(120)102-32-8-13-63(102)78(121)101-31-7-12-62(101)75(118)95-56(35-46-18-24-50(106)25-19-46)69(112)96-57(79(122)123)36-47-37-86-41-88-47/h14-25,37,41-43,51-63,103-106H,3-13,26-36,38-40,81-82H2,1-2H3,(H2,83,107)(H,86,88)(H,89,114)(H,90,111)(H,91,117)(H,92,110)(H,93,109)(H,94,115)(H,95,118)(H,96,112)(H,97,116)(H,98,108)(H,99,113)(H,122,123)(H4,84,85,87)/t42-,43-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-/m0/s1

SMILES Code: C[C@H]1C(N2CCC[C@H]2C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@H](C(N1)=O)CO)=O)NC([C@H](C)N)=O)C(N[C@@H](CC3=CC=C(O)C=C3)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N4CCC[C@H]4C(N5CCC[C@H]5C(N[C@@H](CC6=CC=C(O)C=C6)C(N[C@@H](CC7=CNC=N7)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC8=CC=C(C=C8)O)=O)CCCNC(N)=N)=O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years)

Solubility:
Soluble in DMSO, soluble in water.

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

 POL6326 has successfully completed Phase I clinical trials and is currently being investigated as a stand-alone therapy in a Phase II clinical trial for its efficacy in autologous transplantation of hematopoietic stem cells in multiple myeloma patients. Interim results of the Phase II trial reveal that POL6326 is safe and well tolerated by all enrolled patients. The interim results also show efficacy, in particular a rapid and predictable onset and a dose-dependent mobilization of stem cells. The mobilization, collection of stem cells from the circulating blood (apheresis), analysis and processing of stem cells is completed in one day which represents an important competitive advantage in the hospital compared to standard therapy. (source: http://www.polyphor.com/pol6326.html).  
 
 
 


References